Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks

References

• amfAR, The Foundation of AIDS ResearchStatistics: Women and HIV/AIDS Available from: http://www.amfar.org/about_hiv_and_aids/facts_and_stats/statistics__women_and_hiv_aids/Accessed November 28, 2015
   Google Scholar
• Centers for Disease Control and PreventionNational Women and Girls HIV/AIDS Awareness Day Available from: http://www.cdc.gov/features/womengirlshivaids/Accessed November 28, 2015
   Google Scholar
• SquiresKEGender differences in the diagnosis and treatment of HIVGend Med20074429430718215722
   PubMedGoogle Scholar
• SoonGGMinMStrubleKAMeta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000–2008)AIDS Patient Care STDS201226844445322734949
   PubMed Web of Science ®Google Scholar
• BeldenKASquiresKEHIV infection in women: do sex and gender matter?Curr Infect Dis Rep200810542343118687207
   PubMedGoogle Scholar
• ClarkRASquiresKEGender-specific considerations in the antiretroviral management of HIV-infected womenExpert Rev Anti Infect Ther20053221322715918779
   PubMedGoogle Scholar
• GandhiMAweekaFGreenblattRMBlaschkeTFSex differences in pharmacokinetics and pharmacodynamicsAnnu Rev Pharmacol Toxicol20044449952314744256
   PubMed Web of Science ®Google Scholar
• DelmasMCJadandCDe VincenziIGender difference in CD4+ cell counts persist after HIV-1 infectionAIDS1997118107110739223753
   PubMed Web of Science ®Google Scholar
• PrinsMMeyerLHessolNASex and the course of HIV infection in the pre- and highly active antiretroviral therapy erasAIDS200519435737015750389
   PubMed Web of Science ®Google Scholar
• PrinsMRobertsonJRBrettleRPDo gender differences in CD4 cell counts matter?AIDS199913172361236410597777
   PubMed Web of Science ®Google Scholar
• OfotokunIChuckSKHittiJEAntiretroviral pharmacokinetic profile: a review of sex differencesGend Med20074210611917707845
   PubMed Web of Science ®Google Scholar
• FloridiaMGiulianoMPalmisanoLVellaSGender differences in the treatment of HIV infectionPharmacol Res2008583–417318218708144
   PubMed Web of Science ®Google Scholar
• KoNYLaiYYLiuHYGender differences in HIV manifestations at presentation to care and continuity of care among HIV-infected persons in TaiwanAIDS Care201123101254126321939404
   PubMed Web of Science ®Google Scholar
• NicastriEAngelettiCPalmisanoLGender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapyAIDS200519657758315802976
   PubMed Web of Science ®Google Scholar
• SmithKYTierneyCMollanKOutcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineClin Infect Dis201458455556324253247
   PubMed Web of Science ®Google Scholar
• VenutoCSMollanKMaQSex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202J Antimicrob Chemother201469123300331025159623
   PubMed Web of Science ®Google Scholar
• ViiV HealthcareResult summary for APV30002 Available from: http://www.viiv-clinicalstudyregister.com/result_detail.jsp?protocolId=APV30002&compound=fosamprenavirAccessed November 28, 2015
   Google Scholar
• DeJesusEGatheJKatlamaCVirologic response and tolerability by sex and race in subjects receiving fosamprenavir/ritonavir (FPV/r) BID and lopinavir/ritonavir (LPV/r) BID, each in combination with abacavir/lamivudine QD (the KLEAN study)Abstract presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and PreventionJuly 22–25, 2007Sydney, Australia
   Google Scholar
• SmithKYKumarPPatelPDifferences in virologic response among African-Americans and females regardless of therapy in the HEAT studyAbstract presented at: 5th International AIDS Society Conference on HIV Treatment Pathogenesis and PreventionJuly 19–22, 2009Cape Town, South Africa
   Google Scholar
• SquiresKEJohnsonMYangRComparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE studyJ Antimicrob Chemother201166236337021148235
   PubMed Web of Science ®Google Scholar
• SquiresKEYoungBDeJesusESafety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patientsHIV Clin Trials2010112697920542844
   PubMed Web of Science ®Google Scholar
• SquiresKEYoungBDeJesusESimilar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patientsAIDS201024132019202720613461
   PubMed Web of Science ®Google Scholar
• SquiresKEYoungBDeJesusEARIES 144-week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudineHIV Clin Trials201213523324423134624
   PubMed Web of Science ®Google Scholar
• National Institutes of HealthATP III Guidelines at-a-Glance Quick Desk Reference Available from: https://www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdfAccessed November 28, 2015
   Google Scholar
• Andrade-VillanuevaJHerreraGChiliadePARTEMIS: week 48 safety and efficacy of darunavir/r by gender, age and raceTerapeut Farmacol Toxicol Clin2008123367371
   Google Scholar
• WalmsleySLSquiresKWeissLMultidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with menAIDS200923342943119114862
   PubMed Web of Science ®Google Scholar
• MooreALKirkOJohnsonAMVirologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisitedJ Acquir Immune Defic Syndr200332445246112640206
   PubMed Web of Science ®Google Scholar
• Collot-TeixeiraSDe LorenzoFWatersLImpact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expressionClin Pharmacol Ther200985437537819118379
   PubMed Web of Science ®Google Scholar
• MolinaJMAndrade-VillanuevaJEchevarriaJOnce-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48-week efficacy and safety results of the CASTLE studyLancet2008372963964665518722869
   PubMed Web of Science ®Google Scholar
• AbergJATebasPOvertonETMetabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeksAIDS Res Hum Retroviruses201228101184119522352336
   PubMed Web of Science ®Google Scholar
• MalvestuttoCDAbergJAManagement of dyslipidemia in HIV-infected patientsClin Lipidol20116444746222216062
   PubMedGoogle Scholar
• YoungBSquiresKERossLLInflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIESAIDS Res Hum Retroviruses201329235035823039030
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC)HIV surveillance–United States, 1981–2008MMWR Morb Mortal Wkly Rep2011602168969321637182
   PubMedGoogle Scholar